Osteosarcoma Companies

Top Industry Leaders in the Osteosarcoma Market

Osteosarcoma Key Companies Latest Osteosarcoma Companies Update

Oct 2023: Following the opening of the greenfield manufacturing facility for Eugia Steriles in Visakhapatnam, Andhra Pradesh, Aurobindo Pharma shares increased by 0.5 percent in early trade on October 17. Eugia Steriles is a step-down division of Aurobindo Pharma and a wholly-owned subsidiary of Eugia Pharma Specialities. A phased global supply of generic injectables is anticipated from this unit, which will produce them. CuraTeQ Biologics, a subsidiary of Aurobindo Pharma and a Singapore-based company, inked a Letter of Intent for CMO operations earlier this month. The subsidiary wants to grow its biologics production facilities and investigate the possibility of manufacturing biological contracts.

Nov 2023: A machine learning (ML) tool has been developed by investigators at Johns Hopkins Medicine that can estimate the percent necrosis (PN) in patients with intramedullary osteosarcoma, a type of cancer originating in the center of the bone. PN is the percentage of a tumor considered "dead" and inactive. To accurately determine a patient's chances of survival after chemotherapy, PN calculation is essential. The purpose of PN is to measure the percentage of a tumor that is dead or inactive, which is a measure of the effectiveness of the chemotherapy treatment. When pathologists decipher and annotate whole-slide images (WSIs), thinly cut specimen sections are placed onto slides and examined under a microscope, they compute peripheral nerve injury (PN). These specimens are samples of bone tissue related to intramedullary osteosarcoma that a musculoskeletal pathologist must assess.

List of Osteosarcoma Key companies in the market